Merck signs $290m deal with Orion Corporation for mCRPC candidate ODM-208
Merck has signed a global development and commercialization deal worth $290 million with Orion Corporation for the latter’s investigational candidate ODM-208 and other drugs that ... Read More
Liquid biopsy company ANGLE plc bags pharma services contract
UK-based liquid biopsy company ANGLE plc has won a pharma services contract worth up to $1.2 million from an undisclosed pharma company that is engaged ... Read More
Cancer Targeted Technology gets NIH grant to support CTT1403 trial
Cancer Targeted Technology (CTT), a Seattle-based biotech company, has secured a grant of $1.44 million from the US National Institutes of Health (NIH) to support ... Read More
GSK completes $5.1bn acquisition of Tesaro to boost oncology pipeline
GlaxoSmithKline (GSK), the British pharmaceutical powerhouse, has successfully concluded its $5.1 billion acquisition of Tesaro, a leading oncology-focused biopharmaceutical company based in Waltham, Massachusetts. This ... Read More
Novartis completes $2.1bn acquisition of Endocyte to boost cancer treatment capabilities
Swiss pharmaceutical giant Novartis has officially closed its $2.1 billion acquisition of US-based biopharma company Endocyte, solidifying its position as a leader in radiopharmaceuticals for ... Read More
US biopharma company Endocyte to be acquired by Novartis for $2.1bn
Novartis acquisition of Endocyte : US biopharma company Endocyte has agreed to be acquired by Swiss pharma company Novartis in a deal worth around $2.1 ... Read More
Novartis to expand radiopharmaceuticals portfolio with $2.1bn Endocyte acquisition
Swiss pharmaceutical company Novartis has announced a strategic acquisition of the US-based biopharma firm Endocyte for approximately $2.1 billion. This move aims to bolster Novartis’s ... Read More
Astellas, Pfizer bag Xtandi FDA approval for non-metastatic CRPC
In a significant development, Astellas Pharma and Pfizer have announced that the U.S. Food and Drug Administration (FDA) has expanded the approval of their cancer ... Read More